Skip to main content
. 2021 Apr 2;12:642528. doi: 10.3389/fimmu.2021.642528

Figure 2.

Figure 2

CAR T cells redirected to CD80/86 significantly suppress the tumorigenesis of subcutaneous xenografts. (A–C) NOD/SCID/IL2Rg−/− mice were subcutaneously injected with 2 × 105 of Raji, RL, or NALM6 cells and were intravenously administered human T cells transduced with either chimeric CTLA4 or GFP. Blank control groups comprised mice intravenously administered non-transduced T cells (2 × 105 cells, five mice/group). The tumor weight of the Raji, RL, and NALM6 xenografts was weighed after 28 days. The tumor volumes in the CDX models were measured and calculated every 7 days. (D) Representative flow cytometric analyses of CD80 and CD86 expression in a xenograft comprising tumor cells from a B cell lymphoma patient. (E) NOD/SCID/IL2Rg−/− mice were subcutaneously transplanted with patient-derived xenografts (PDXs) of B cell lymphoma to create PDX mouse models, which were treated with CTLA4-T, GFP-T, or non-transduced T cells when the tumor volume reached 50 to 100 mm3. The total number of GFP-positive T cells injected per mouse was 2 × 105. Tumors in the mice in all three groups (five mice/group) were weighed at the end of the experiment. The tumor volume was measured and calculated every 5 days. Data are shown as the mean ± SD from independent experiments. One-way ANOVA; significance values: *P < 0.05; **P < 0.01; ***P < 0.001.